TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Target Price of $121.10

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned an average recommendation of “Hold” from the thirteen analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $121.00.

TMDX has been the subject of several analyst reports. Barclays began coverage on TransMedics Group in a report on Wednesday. They issued an “overweight” rating and a $120.00 price target for the company. Canaccord Genuity Group restated a “buy” rating and set a $124.00 price objective on shares of TransMedics Group in a report on Tuesday, June 30th. UBS Group lowered their price objective on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Zacks Research lowered TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of TransMedics Group in a research report on Friday, September 11th.

Insider Buying and Selling

In related news, Director David Weill acquired 1,336 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was bought at an average price of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. The trade was a 8.87% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Silvant Capital Management LLC purchased a new stake in TransMedics Group in the second quarter valued at approximately $26,000. North Star Investment Management Corp. acquired a new position in TransMedics Group during the first quarter worth approximately $30,000. Ascentis Independent Advisors purchased a new position in TransMedics Group during the first quarter worth approximately $30,000. State of Wyoming purchased a new position in TransMedics Group during the second quarter worth approximately $31,000. Finally, Ancora Advisors LLC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at $33,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $81.07 on Monday. The company has a market cap of $2.80 billion, a PE ratio of 20.84, a price-to-earnings-growth ratio of 1.10 and a beta of 1.94. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The company has a 50-day simple moving average of $85.92 and a 200-day simple moving average of $84.22.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business’s quarterly revenue was up 20.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.92 EPS. On average, equities analysts anticipate that TransMedics Group will post 1.46 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.